Diurnal preference, mood and the response to morning light in relation to polymorphisms in the human clock gene **PER3**

M. Turco\(^1\), A. Biscontin\(^2\), M. Corrias\(^{1,3}\), L. Caccin\(^2\), M. Bano\(^3\), F. Chiaromanni\(^2\), M. Salamanca\(^3\), D. Mattei\(^3\), C. Salvoro\(^2\), G. Mazzotta\(^2\), C. De Pittà\(^2\), B. Middleton\(^3\), D. J. Skene\(^3\), S. Montagnese\(^4\) & R. Costa\(^2\)

**PER3** gene polymorphisms have been associated with differences in human sleep-wake phenotypes, and sensitivity to light. The aims of this study were to assess: i) the frequency of allelic variants at two **PER3** polymorphic sites (rs57875989 length polymorphism: **PER3**\(^4\), **PER3**\(^5\); rs228697 SNP: **PER3**\(^C\), **PER3**\(^G\)) in relation to sleep-wake timing; ii) the effect of morning light on behavioural/circadian variables in **PER3**\(^4\)/**PER3**\(^4\) and **PER3**\(^5\)/**PER3**\(^5\) homozygotes. 786 Caucasian subjects living in Northern Italy donated buccal DNA and completed diurnal preference, sleep quality/timing and sleepiness/mood questionnaires. 19 **PER3**\(^4\)/**PER3**\(^4\) and 11 **PER3**\(^5\)/**PER3**\(^5\) homozygotes underwent morning light administration, whilst monitoring sleep-wake patterns and the urinary 6-sulphatoxymelatonin (aMT6s) rhythm. No significant relationship was observed between the length polymorphism and diurnal preference. By contrast, a significant association was observed between the **PER3**\(^G\) variant and morningness (OR = 2.10), and between the **PER3**\(^G\) - **PER3**\(^4\) haplotype and morningness (OR = 2.19), for which a mechanistic hypothesis is suggested. No significant differences were observed in sleep timing/aMT6s rhythms between **PER3**\(^5\)/**PER3**\(^5\) and **PER3**\(^4\)/**PER3**\(^4\) subjects at baseline. After light administration, **PER3**\(^4\)/**PER3**\(^4\) subjects advanced their aMT6s acrophase (p < 0.05), and showed a trend of advanced sleep-wake timing. In conclusion, significant associations were observed between **PER3** polymorphic variants/their combinations and both diurnal preference and the response to light.

Clock genes and their products are associated with the current molecular model for the genesis of circadian rhythms\(^1\). Allelic variants of clock genes affect the period and the phase of circadian rhythms\(^1\). An important component of the biological clock is the **Period** (**PER**) gene family. The heterodimers formed by **PER3** protein with **PER1/2** and **cryptochrome** 1/2 (**CRY1/2**) enter the nucleus, inhibit **CLOCK/BMAL1**-mediated transcription\(^3\), thus contributing to the output pathway of circadian oscillations\(^1\). The human **PER3** gene shows higher levels of polymorphism compared to the other **PER** paralogs\(^2\), suggesting that **PER3** may account for individual differences in human circadian and sleep phenotypes.

The coding region of the **PER3** gene contains a variable-number tandem-repeat (VNTR) polymorphism, i.e. a motif encoding 18 amino acids is repeated either four (**PER3**\(^4\)) or five (**PER3**\(^5\)) times in exon 18\(^6\) (rs57875989, NM_001289861.1:c.3002-13\_3042del54). The repeated unit contains a cluster of putative phosphorylation sites, and the polymorphism may influence **PER3** function. There is some evidence that, in humans, **PER3** may be related to diurnal preference, or the personal inclination to be more/less active at different times of the waking day. The **PER3**\(^5\) allelic variant has been associated with physiological and pathological eveningness\(^6,7\) while the **PER3**\(^3\) allele has been associated with morningness\(^7\). In addition, the **PER3**\(^5\) allele has been associated with enhanced suppression of nocturnal melatonin by administration of light at night\(^8\). However, the effect of light in

---

1Department of Medicine, University of Padova, Padova, Italy. 2Department of Biology, University of Padova, Padova, Italy. 3Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom. S. Montagnese and R. Costa jointly supervised this work. Correspondence and requests for materials should be addressed to R.C. (email: rodolfo.costa@unipd.it)

Received: 7 February 2017  
Accepted: 16 June 2017  
Published online: 31 July 2017
PER3, most likely altering the binding properties of the protein. The scaffolding protein NCK contains SH3 bind-
prevalent in evening types. The P864A substitution would disrupt two potential SH3-binding motif domains in
786 subjects (541 females); average HÖ score was 50.2
intermediate types 7.7
uted as follows: 22 extreme evening (3%), 147 moderate evening (19%), 436 intermediate (55%), 163 moderate

Table 1. PER3 genotypes at rs57875989 and minor allele frequencies, by diurnal preference. MAF: Minor Allele
Frequency. No preferential associations between genotype/allele and diurnal preference were observed (Wald
test: p = 0.737). This held true also when intermediate types were excluded and extreme morning/morning
types and extreme evening/evening types were pooled (Cochran-Armitage test \( \chi^2 = 0.069, p = 0.793 \)).

| rs57875989 | Extreme Morning n (%) | Morning n (%) | Intermediate n (%) | Evening n (%) | Extreme evening n (%) | Total n (%) | MAF |
|------------|-----------------------|--------------|-------------------|--------------|-----------------------|------------|-----|
| All        | 4/4                   | 7 (38.9)     | 59 (43.7)         | 142 (43.0)   | 57 (43.2)             | 271 (39.9) | 0.3719 |
|            | 4/5                   | 6 (33.3)     | 54 (40.0)         | 183 (48.9)   | 56 (42.4)             | 311 (45.8) |     |
|            | 5/5                   | 5 (27.8)     | 22 (16.3)         | 49 (13.1)    | 19 (14.4)             | 97 (14.3)  |     |
| Females    | 4/4                   | 6 (46.1)     | 45 (47.4)         | 104 (39.5)   | 40 (44.9)             | 198 (42.0) | 0.3599 |
|            | 4/5                   | 4 (30.8)     | 34 (35.8)         | 126 (47.9)   | 37 (41.6)             | 207 (43.9) |     |
|            | 5/5                   | 3 (23.1)     | 16 (16.8)         | 33 (12.6)    | 12 (13.5)             | 66 (14.0)  |     |
| Males      | 4/4                   | 1 (20.0)     | 14 (35.0)         | 38 (34.2)    | 17 (39.5)             | 73 (35.1)  | 0.3990 |
|            | 4/5                   | 2 (40.0)     | 20 (50.0)         | 57 (51.3)    | 19 (44.2)             | 104 (50.0) |     |
|            | 5/5                   | 2 (40.0)     | 6 (15.0)          | 16 (14.5)    | 7 (16.3)              | 31 (14.9)  |     |

the morning, which is often utilised for treatment purposes (i.e. seasonal affective disorder, delayed sleep-wake
rhythms, irregular schedules etc.\(^9,\)\(^10\)) has not been tested within this context.

Recently, a SNP (rs228697, NM_001289861.1:c.2590 C > G) in exon 17 of PER3 that causes the amino acid
substitution P864A has also been associated with diurnal preference\(^11\), with the 2590G allele (864 A) being more

In addition, the effect of an 8-day course of morning light administration on behavioural and circadian variables
in a group of well-characterised PER3/PER3\(^4\) and PER3/PER3\(^5\) homozygotes was also studied.

Results

Genotype, diurnal preference and sleep-wake variables. The HÖ questionnaire was completed by
786 subjects (541 females); average HÖ score was 50.2 ± 10.4 (range: 21–78). Diurnal preference was distrib-
uted as follows: 22 extreme evening (3%), 147 moderate evening (19%), 436 intermediate (55%), 163 moderate
morning (21%) and 18 extreme morning (2%). HÖ scores were in agreement with daily sleep-wake timing in the
494 subjects for whom sleep diaries were also available [i.e. wake up time (decimal h): evening types 8.5 ± 1.2 vs.
intermediate types 7.7 ± 0.7 vs. morning types: 6.9 ± 0.6; ANOVA p < 0.001, each group significantly different
from all others on post-hoc, with p < 0.001].

| | | | | | | |
|---|---|---|---|---|---|---|
| rs57875989 | Extreme Morning n (%) | Morning n (%) | Intermediate n (%) | Evening n (%) | Extreme evening n (%) | Total n (%) | MAF |
| All | 4/4 | 7 (38.9) | 59 (43.7) | 142 (43.0) | 57 (43.2) | 271 (39.9) | 0.3719 |
| | 4/5 | 6 (33.3) | 54 (40.0) | 183 (48.9) | 56 (42.4) | 311 (45.8) |     |
| | 5/5 | 5 (27.8) | 22 (16.3) | 49 (13.1) | 19 (14.4) | 97 (14.3) |     |
| Females | 4/4 | 6 (46.1) | 45 (47.4) | 104 (39.5) | 40 (44.9) | 198 (42.0) | 0.3599 |
| | 4/5 | 4 (30.8) | 34 (35.8) | 126 (47.9) | 37 (41.6) | 207 (43.9) |     |
| | 5/5 | 3 (23.1) | 16 (16.8) | 33 (12.6) | 12 (13.5) | 66 (14.0) |     |
| Males | 4/4 | 1 (20.0) | 14 (35.0) | 38 (34.2) | 17 (39.5) | 73 (35.1) | 0.3990 |
| | 4/5 | 2 (40.0) | 20 (50.0) | 57 (51.3) | 19 (44.2) | 104 (50.0) |     |
| | 5/5 | 2 (40.0) | 6 (15.0) | 16 (14.5) | 7 (16.3) | 31 (14.9) |     |

This population was shown to be in Hardy-Weinberg equilibrium (\( \chi^2 = 0.259, DF = 1, p = 0.610 \), Table 1), with
no significant differences in genotype distribution between females and males (\( \chi^2 = 2.976, DF = 2, p = 0.226 \)).

The distribution of diurnal preference in relation to VNTR genotype is presented in Table 1. No preferential asso-
ciations between genotype/allele and diurnal preference were observed (Wald test: p = 0.737). This also held true
when intermediate types were excluded and when extreme morning/morning types and extreme evening/evening
types were pooled (Cochran-Armitage test \( \chi^2 = 0.069, p = 0.793 \)).

Subjects with available VNTR genotype (and available, residual DNA) plus diurnal preference data were
selected for SNP rs228697 genotype determination, based on their diurnal preference score. Morning/extreme
morning and evening/extreme evening types were selected (i.e. intermediate types were excluded) to maximise
the likelihood of detecting an association, if any, between the PER3\(^4\) and PER3\(^5\) variants and diurnal prefer-
ence. All required data were available for n = 103 morning/extreme morning types and n = 106 evening/extreme
evening types. This population was also shown to be in Hardy-Weinberg equilibrium (\( \chi^2 = 0.248, DF = 1, p = 0.618 \)), with no significant differences in SNP genotype distribution between females and males (\( \chi^2 = 0.184, DF = 2, p = 0.912 \)). The distribution of the combined genotypes of both polymorphic sites is shown in Table 2,
for morning and evening types separately. Analysis of this sample confirmed the absence of any preferential
association between the VNTR polymorphism and diurnal preference (Cochran-Armitage test \( \chi^2 = 0.467, DF = 1, p = 0.494 \)). By contrast, for the SNP rs228697 an association was observed between the PER3\(^4\) variant and morningness (Cochran-Armitage test \( \chi^2 = 6.998, DF = 1, p = 0.008, OR = 2.10, 95\% CI = 1.21–3.65 \)). Allelic co-
ocurrence at the two sites (Table 2) shows that the PER3\(^4\) variant was almost in complete linkage disequi-
librium with the PER3\(^4\) variant (\( D' = 0.912 \)). The conditional haplotype test showed a significant association of
the PER3\(^4\)-PER3\(^4\) haplotype with morningness (likelihood ratio \( \chi^2 = 8.240, DF = 2, p = 0.016, OR = 2.19, 95\% CI = 1.17–4.08 \)). This was mostly due to the PER3\(^3\) association with morningness. Both allelic and haplotype
associations remained significant (p < 0.05) after correction for multiple comparisons.
There was no significant association with either polymorphism alone (n = 331). In particular, PER3/G - PER3/G alleles (n = 103) MAF(G) MAF(5) were less sleepy in the morning and more sleepy in the early afternoon/early evening compared to their PER3/G counterparts (diaries available for 117 subjects; Table 3). However, these differences were not significant after correction for multiple comparisons (FDR adjusted p > 0.05). Although sample numbers became small, individuals with two PER3/G alleles (n = 5) tended to exhibit even earlier sleep-wake times than their counterparts with one or no PER3/G alleles [i.e. wake up time (decimal h): 6.8 ± 0.8 (two PER3/G alleles) vs. 7.7 ± 1.5 (one PER3/G allele) vs. 8.2 ± 1.2 (no PER3/G alleles), p = 0.057]. Individuals with any degree of PER3/G - PER3/G association (i.e. heterozygotes or homozygotes for the PER3/G together with one or two PER3/G4) woke up significantly earlier, slept less and reported worse sleep quality compared to their counterparts without the association (Table 3). However, these differences were not significant after correction for multiple comparisons (FDR adjusted p > 0.05).

The KSS and mood scales were completed by 388 subjects (36%, 278 females). Sleepiness showed significant variation over the waking hours of the day, and there was a significant interaction genotype*time for the VNTR polymorphism (n = 331). In particular, PER3/G-PER3/G subjects (n = 59) were less sleepy in the morning and more sleepy in the early afternoon/early evening compared to their PER3/G-PER3/G (n = 135) and PER3/G-PER3/G (n = 137) counterparts (genotype: p = 0.195, time: p < 0.001, genotype*time: p = 0.029; post hoc significant at several time points; Fig. 1). There was no significant relationship between KSS scores and the SNP alone or in combination with the VNTR polymorphism (n = 72). Self-rated mood also showed significant variation over the waking hours of the day but no significant association with either polymorphism alone (n = 331 for the VNTR polymorphism and n = 72 for the SNP, respectively). However, when the PER3/G - PER3/G association was considered, there was a significant interaction between genotype and mood, individuals with the association (n = 19) having

### Table 2. Genotypes and minor allele frequencies at the two PER3 polymorphic sites, by diurnal preference.

|   | PER3/G Present (n = 33) | PER3/G Absent (n = 84) | PER3/G - PER3/G Present (n = 32) | PER3/G - PER3/G Absent (n = 85) |
|---|------------------------|------------------------|---------------------------------|---------------------------------|
|   | Bed time (decimal h) | 24.9 ± 1.5             | 24.3 ± 1.3                       | 24.1 ± 1.5                       |
|   | Time to fall asleep (min) | 16.0 ± 11.9           | 13.2 ± 10.5                      | 16.4 ± 12.0                      |
|   | Sleep onset (decimal h) | 24.6 ± 1.6             | 24.9 ± 1.3                       | 24.7 ± 1.5                       |
|   | Wake up time (decimal h) | 7.6 ± 1.4*             | 8.2 ± 1.2                        | 7.6 ± 1.4*                       |
|   | Get up time (decimal h) | 8.0 ± 1.4              | 8.5 ± 1.2                        | 8.0 ± 1.4                        |
|   | Naps (n)              | 0.1 ± 0.2              | 0.2 ± 0.3                        | 0.1 ± 0.2                        |
|   | Length of sleep (h)   | 6.9 ± 0.9              | 7.3 ± 0.8                        | 6.9 ± 0.8*                       |
|   | Sleep efficiency (%)  | 87.3 ± 8.7             | 89.2 ± 7.0                       | 87.3 ± 8.8                       |
|   | Sleep quality (1–10 scale) | 4.2 ± 1.5*             | 3.7 ± 1.3                        | 4.2 ± 1.5*                       |
|   | PSQI global score [0–21] | 6.9 ± 4.2*              | 5.4 ± 2.9                        | 7.1 ± 4.2*                       |

**Table 3.** Sleep-wake timing and sleep quality indices in relation to the presence/absence of the PER3/G allele and the PER3/G - PER3/G association. *p < 0.05 on direct comparisons, not confirmed after correction for multiple comparisons (FDR adjusted p > 0.05). °Data available for 37/90 participants with/without the PER3/G allele and for 36/91 participants with/without the PER3/G - PER3/G association. PSQI: Pittsburgh Sleep Quality Index.
a significantly worse mood in the early evening hours compared to those without (n = 53) (genotype: p = 0.756, time: p = 0.045, genotype*time: p = 0.020; post hoc significant from 18:30 to 21:30 h; Fig. 2).

**Response to light.** No significant differences were observed in sleep timing and/or aMT6s rhythms between PER34/PER34 and PER35/PER35 individuals at baseline (Table 4). After light administration, 15 subjects (12 PER34/PER34, 3 PER35/PER35) showed an advance in their aMT6s acrophase, 3 a delay in aMT6s acrophase (all PER34/PER35) and 12 no significant change (7 PER34/PER34, 5 PER35/PER35). Thus, when the direction of phase shift was accounted for, significant differences were observed between the response to light in the two genotypes, with PER34/PER35 subjects advancing their aMT6s acrophase by approximately half an hour compared to their
**PER3**/*PER3* counterparts (−26 ± 32 vs. +3 ± 43 min; p = 0.037; Fig. 3). Absolute value changes (i.e. not taking into account of their direction) were comparable in the two groups (30 ± 29 min in **PER3**/*PER3* participants vs. 30 ± 30 min in **PER3**/*PER3* participants). No significant changes were observed in other aspects of the aMT6s rhythms (mesor, amplitude, total amount produced) in relation to light administration.

**PER3**/*PER3* subjects (n = 19) also exhibited a trend (0.05 < p < 0.1) for a stronger response to light in terms of an earlier sleep onset and wake up times after light administration compared to their **PER3**/*PER3* counterparts (n = 11). In both **PER3**/*PER3** and **PER3**/*PER3** groups, the course of light treatment significantly reduced the number of awakenings (from approximately 1 per night to 0.5 per night; genotype: p = 0.194, time: p = 0.003, genotype×time: p = 0.694).

While the SNP was only available in 12 individuals who underwent light administration and statistical power was insufficient for a full analysis, the tendency for individuals with any degree of **PER3**−/−**PER3** association (one or two **PER3** to together with one or two **PER3**, n = 3 out of the 12 available) to show earlier wake-up times and an earlier aMT6s acrophase was confirmed.

**Discussion**

This is the first study carried out in a large, healthy population of Caucasian individuals living in Northern Italy regarding the relationship of two clock gene **PER3** polymorphic sites (the rs228697 SNP and the **PER3**−**PER3** rs57875989 VNTR polymorphism) and a set of sleep-wake phenotypes, including diurnal preference, sleep-wake timing and mood.

While several studies have implicated the *Period* genes **PER1** and **PER2** in the molecular timekeeping of the master circadian clock, the role of **PER3** is less clear. In a study assessing **PER1**-promoter-driven luciferase expression in cultured suprachiasmatic nuclei (SCN), pituitary, and lung explants from **PER2**−/− and **PER3**−/− mice, Pendergast *et al.* observed that the period of **PER1-luc** expression in **PER2**−/− SCN explants was 1.5 hours shorter than that of **PER2**+/+. In the same study, **PER3**−/− and **PER3**+/+ mice exhibited comparable SCN explants, while the period/phase of their pituitary and lung explants were different, and were abnormal in **PER3**−/−. These observations suggest that the function of each **PER** gene may be tissue-specific. In a subsequent study, Pendergast *et al.* observed shortening of periods in some peripheral tissues but not in the SCN of **PER3**−/− mice compared to wild-types. Such period shortening resulted in advanced phases, indicating that some degree of internal misalignment may occur in **PER3**−/− mice. Based on the circadian features/light sensitivity of both **PER3**−/− mice and rare **PER3** polymorphic variants, Zhang *et al.* have recently hypothesised that **PER3** may affect the clock via a stabilising function on **PER1**/**PER2**.

In the present study, no relationship was observed between the **PER3**− **PER3** VNTR polymorphism and diurnal preference. The available literature is conflicting in this respect, with at least three studies documenting this association4, 16, 17 and others failing to replicate it18-20. Several factors could explain these discrepancies. For example, Pereira and colleagues21 have suggested that latitude may be implicated, together with differences in the length of days, climate and temperature variations throughout the year. However, two of the conflicting studies were based in the United Kingdom, thus on populations sharing similar environmental conditions17, 18. It is reasonable that the diurnal preference phenotype might be multifactorial in origin, with genetic factors being more or less obvious depending on the features of the population, and the varying weight of other factors.

Melatonin production, subjective sleepiness and waking slow electroencephalographic activity are reduced by the exposure to 460 nm blue monochromatic light during the biological night11, 22. Such light responses have been reported to be stronger in **PER3**−/−**PER3** compared to **PER3**+/+ healthy subjects8, thus it has been suggested that **PER3** variants may contribute to the inter-individual variability of the non visual responses to light8. All protocols testing such a hypothesis have been performed within the context of light-induced suppression of nocturnal melatonin production4, 21, with administration of light at night. In the clinical/therapeutic setting, however, bright light is often used to advance circadian phase, and is thus delivered at the beginning of the day23. Hence our attempt to test light responses in relation to genotype in the setting of morning light administration. In our study, despite large within group variability, morning light showed more prominent phase shifting effects.
in PER3\(^{4}\)/PER3\(^{4}\) compared to PER3\(^{5}\)/PER3\(^{4}\) subjects. This is reasonable, as supplementation of morning light may be more effective in individuals who are intrinsically less sensitive to light (PER3\(^{3}\)/PER3\(^{4}\) subjects\(^{8}\)) and thus less likely to have already benefited from the alerting effect of getting up and being exposed to standard room lighting in the early morning. This interpretation is supported by our data on the time-course of subjective sleepiness in PER3\(^{4}\)/PER3\(^{4}\) versus PER3\(^{3}\)/PER3\(^{4}\) subjects. Interestingly, all three subjects who showed a somewhat paradoxical response to morning light, delaying their aMT6s acrophase, were PER3\(^{4}\)/PER3\(^{3}\), in line with previous findings on light sensitivity in this group\(^{8}\). Morning light supplementation reduced the number of night awakenings in all treated subjects, confirming its sleep consolidating effects\(^{8}\). These data are clinically relevant as they could help: i) understanding blunted and excessive/paradoxical responses to light administration; ii) refining patient selection and monitoring during a course of chronotherapy.

In this study, we observed a novel, strong association between the PER3\(^{5}\) allele (rs228697 SNP) and morningness, and an even stronger one between the PER3\(^{4}\) - PER3\(^{3}\) haplotype and morningness. This was confirmed by daily sleep diaries, which documented earlier sleep onset (trend) in PER3\(^{3}\) and PER3\(^{5}\) - PER3\(^{4}\) subjects. However, these differences were not significant after correction for multiple comparisons. Our findings contrast, to some extent, with those of Hida and colleagues\(^{11}\), who documented a weak albeit significant association between the PER3\(^{5}\) allele and eveningness. Interestingly, and despite large within group variability, in our study PER3\(^{5}\) - PER3\(^{4}\) subjects also showed a different time-course of their mood over the waking hours, with significantly lower mood scores in the late afternoon/early evening. Rare PER3 variants have previously been linked to depressive behaviour both in humans with advanced sleep phase syndrome and in a mouse model mimicking rare PER3 human mutations\(^{14}\). In addition, progressive worsening of mood has been documented over the waking hours of the day in humans\(^{4}\). This may of course be modulated by diurnal preferences\(^{14}\).

Haplotype frequency pattern analysis (Table 2) suggests a tentative parsimonious phylogeny relationship accounting for the origin of the four haplotypes. We hypothesize that PER3\(^{4}\) - PER3\(^{5}\) and PER3\(^{3}\) - PER3\(^{4}\) haplotypes could be the ancestral ones, and that the 4-units to 5-units expansion of the repeated region occurred on a PER3\(^{5}\) - PER3\(^{4}\) background, thus originating the PER3\(^{3}\) - PER3\(^{4}\) haplotype. A very low recombination rate between the PER3\(^{3}\) - PER3\(^{4}\) and PER3\(^{5}\) - PER3\(^{4}\) haplotypes, due to the very small distance between the two polymorphic sites (2348 base pairs), could thus explain the almost complete absence of the PER3\(^{3}\) - PER3\(^{4}\) haplotype. Interestingly, the carrier and estimated haplotype frequencies for the rs228697 and rs57875989 polymorphisms described by Ebisawa and colleagues\(^6\) reflect the distribution observed in this study, with no PER3\(^{3}\) - PER3\(^{5}\) association.

The association between the PER3\(^{5}\) - PER3\(^{4}\) haplotype and morningness could reflect the specific effects of the PER3\(^{4}\) variant on the circadian molecular cycle. As pointed out by Hida and colleagues\(^{11}\), the P864A amino acid substitution affects the hydrophobicity of the protein, altering its secondary structure and its phosphorylation dynamics. Indeed, the substitution could disrupt two potential SH3-binding domains ([LPDPP-864] and [PP-864-VP]) which could, in turn, impinge on the interaction between PER3 and NCK. NCK is a scaffolding protein with SH3 domains which has been implicated in the PER3 interaction with a CKI. Such interaction regulates PER accumulation/stability throughout the circadian cycle\(^{12}\). In this scenario, it can be hypothesised that the PER3\(^{4}\) protein is more stable and accumulates faster in the cytoplasm compared to the PER3\(^{3}\) protein. Therefore, PER3\(^{4}\) is likely to enter the nucleus earlier than PER3\(^{3}\) to exert a negative feedback on the transcription of PER and CRY genes. This would result in shorter periodicity in free running conditions, and phase advancing of some circadian phenotypes, which fits with our observed association between the ‘faster accumulating’ PER3\(^{4}\) protein and morningness. While PER3\(^{4}\) appears to affect mainly peripheral clocks\(^{13}\),\(^{14}\), it cannot be excluded that at least some of these effects may feedback to the SCN, contributing to the modulation of the phase of sleep timing. Based on experiments in primary dermal cells, Brown et al.\(^2\) suggested that human diurnal preference may be influenced by cellular components that affect the amplitude and phase of the circadian oscillator. Ferrante et al.\(^{25}\) observed that PER3 circadian expression in a peripheral tissue (hair follicle) of morning types was 1.5 hours earlier than that of intermediate types, and 3 hours earlier than that of evening-types. If our hypothesis of the effects of the P864A polymorphism on the molecular mechanisms underlying the oscillation is correct, a 2–3 hour phase difference in peripheral clocks in PER3\(^{4}\) and PER3\(^{5}\) bearing individuals could modulate the phase of their sleep.

The contribution of the PER3\(^{3}\) VNTR variant, albeit modest, in association with PER3\(^{4}\) in defining a morning phenotype is also in line with the proposed model, because the number of putative phosphorylation sites situated on the repeats are fewer in PER3\(^{3}\) compared to PER3\(^{5}\). This could result in faster cytoplasm accumulation kinetics and, in turn, in negative feedback and phase advancing. It is possible that this may also affect the sensitivity to light. Indeed, it has been demonstrated that light induces a larger phase delay (or smaller phase advance) in different, rare human PER3 variants, which results in abnormal entrainment\(^{15}\).

Of the five non synonymous SNPs which Ebisawa and colleagues originally implicated in the pathogenesis of delayed sleep phase syndrome, one (rs10462020, which causes a V674G substitution) has also been associated with diurnal preference by Johansson and colleagues\(^{20}\). Another one (rs2640909) causes a M1037T substitution, which alters the hydrophobicity of the PER3 protein, possibly affecting PER3 auto-feedback\(^{27}\). This polymorphism was associated with morningness by Ojeda and colleagues\(^{27}\) but not by Hida and colleagues\(^{11}\).

In conclusion, significant associations were observed between the PER3\(^{5}\) polymorphic variant in rs228697 (alone and in combination with the PER3\(^{4}\) variant in rs57875989) and morningness, as well as the course of mood over the waking hours of the day.

**Methods**

**Participants.** A sample of 786 subjects describing themselves as Caucasian and living in Northern Italy [531 females, age 28.6 ± 12.5 (range 18–79)] were recruited in Padova, Italy, during popular science events (January 2012, September 2013 and September 2014). Subjects were excluded if they had significant medical history, any chronic disease, or took regular medication, except for oral contraceptives. All volunteers were asked to donate
a buccal DNA sample (brushing the internal cheek surface firmly for about 15 seconds with a swab; n = 679 accepted), and to complete a sleep-wake assessment including diurnal preference [Horne - Ostberg questionnaire (HO questionnaire)]31, night sleep quality [Pittsburgh Sleep Quality Index (PSQI)]30, Karolinska Sleepiness Scale (KSS)32, mood (visual-analogue 1–10 scale) and habitual sleep timing (sleep diaries). The HO questionnaire was completed during the popular science initiative, with the same researchers providing instructions and answering any questions. The remaining questionnaires and diaries were completed by the participants at home, in the subsequent two-three weeks. Addressed, stamped envelopes were provided; 550 (51%) were returned, with partial or complete information. Participants who provided a readable, viable e-mail address (98%) were subsequently sent a summary report of their sleep-wake assessment and genotype. A brief description of the questionnaires and diaries utilized is provided below.

Study protocols were approved by the Padova University Hospital Ethics Committee (Medical Bio-bank and 3639/AO/15 for light administration) and conducted according to the Declaration of Helsinki (Hong Kong amendment) and good clinical practice (European) guidelines. All methods were performed in accordance with the above ethical guidelines and regulations. All participants provided written, informed consent.

Sleep-wake assessment. The HO questionnaire was used to assess diurnal preference. The total score ranges from 16 to 86: scores <41 define evening (extremely evening <30) types, scores ≥59 define morning (extremely morning ≥70) types, and scores between 42 and 58 intermediate types31.

The PSQI was used to assess night sleep quality over the preceding month. Questionnaire responses generate seven components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction), which are summed to provide the PSQI global score (range: 0–21); scores of >5 identify ‘poor’ sleepers30,31.

The KSS was used to assess daytime sleepiness. Participants rated their subjective sleepiness over the previous 10 minutes, from 1 (very alert) to 9 (very sleepy, fighting sleep, difficulty staying awake)31. In this particular instance, participants were provided with a set of KSS sheets and asked to complete them on an hourly basis over the waking hours of a typical working/studying day, from get-up to bed-time.

Mood visual-analogue scale sheets were also provided (‘Please rate your mood from 1–10 on this scale’, with 10 being marked as best) and participants asked to complete them on an hourly basis over the waking hours of a typical working/studying day, from get-up to bed-time31.

Sleep diaries were completed daily that included a record of bed-time, sleep onset, time to fall asleep, wake-up time, get-up time, number/duration of any night awakenings or daytime naps. Relevant metrics were calculated, including sleep onset latency, wakefulness after initial sleep onset, total sleep time, total time spent in bed, sleep efficiency (time asleep out of total time in bed, as a percentage), and a subjective appraisal of each night’s sleep quality (1–10, with 10 being the negative extreme)31. Participants were instructed to complete the sleep diary each morning, after every night sleep, for 12 days, to include a week-end. Sleep diaries were also completed during the light administration protocol (vide infra) and sleep data were considered both singly and as averages pre- (study days 2–4, Tuesday to Thursday) and during light administration (study days 9–11, also Tuesday to Thursday).

Genotyping. PER34 – PER35 VNTR (Genoma, Build GRCh38, chrom1, start 7829867). Genotyping was performed using polymerase chain reaction (PCR) with the primers described by Ebisawa et al.6 (Supplementary Table 1). The polymerase mixture was prepared in a 20 µl final volume and was composed of 10.6 µl sterile water; 4 µl 5X Taq buffer; 1 µl of 10 mM dNTPs mix; 1 µl of 10 µM Reverse primer; 1 µl of 10 µM Forward primer; 2 µl Genomic DNA; and 2U GoTaq DNA Polymerase (Promega). The amplification conditions were: 94 °C for 3 minutes, then 30 cycles of 94 °C for 1 minute, 55 °C for 1 minute, 72 °C for 1 minute and a final elongation of 72 °C for 10 minutes. Agarose gel electrophoresis was used to identify whether individuals were heterozygous or homozygous for either of the PER3 repeat alleles. For the subgroup of 209 subjects who were also genotyped for SNP rs2286971 (vide infra), genotyping by gel electrophoresis was validated by GeneScan analysis by using the same primer pair proposed by Ebisawa et al.6 but with a HEX-labelleled version of the forward primer. Detailed primer sequences are listed in Supplementary Table 1. A negative and two positive controls (PER34 and PER35) were included in each test performed.

SNP rs2286971 (C/G – > P/A) (Genoma, Build GRCh38, chrom1, 7827519). The detection of the C2590G (P864A) polymorphism was performed by a double fluorescent tetra-primer amplification refractory mutation system PCR (dF-T-ARMS-PCR)34. Two allele-specific primers of the dF-T-ARMS-PCR protocol. The specificity of each allele-specific primer is conferred by the identity of the terminal 3' nucleotide with one of the two possible single nucleotide variations. The two different fluorescent dyes (FAM and HEX) used to specifically label the two allele-specific primer pairs, as well as the significantly different length of their amplicons, allowed for easily distinguishable signals by GeneScan analysis (Peak Scanner Software v1.0; Thermo Fisher Scientific). Primer sequences are detailed in Supplementary Table 1. PCR was performed in a 50 µl final volume and was composed of 27.6 µl sterile water; 10 µl 5X Taq Buffer; 1 µl of 10 mM dNTPs mix; 1 µl of 10 µM Forward and Reverse primers; 5 µl Genomic DNA; and 2U GoTaq DNA Polymerase (Promega). The thermal cycling conditions were as follows: 2 minutes denaturation at 95 °C, followed by 35 cycles of 15 seconds denaturation at 95 °C, 20 seconds annealing at 57 °C, 1 minute elongation at 72 °C, and a final 3-min elongation cycle at 72 °C. Capillary electrophoresis was performed with an ABI 3100 Genetic Analyzer (Applied Biosystems) at BMR Genomics (Padova, Italy). The size of the products was determined using the GeneScan 400 HD ROX size standard (Thermo Fisher). A negative and two positive controls (PER34 and PER35) were included in each test performed.
Morning light administration protocol. A subgroup of 30 subjects who were homozygous for the length polymorphism [19 PER3/PER3 (27 ± 9 yrs, 15 females) and 11 PER3/PER3 (26 ± 10 yrs, 8 females)] underwent a course of morning light administration, whilst monitoring sleep–wake patterns and melatonin rhythmicity.

Experimental design. The study was conducted over 12 days and sleep–wake diaries completed daily (Table 5). The KSS was completed hourly over the waking hours of days 1 (pre-light) and 11 (end of light) (Table 5). Two separate 56-hour urine collections (over 2 days and 3 nights, at 4 hour intervals during the day and 8 hour intervals at night) were obtained on study days 1–3 (pre-light) and 9–11 (end of light) (Table 5) for assessment of the urinary melatonin metabolite 6-sulfatoxymelatonin (aMT6s; vide infra) rhythms. Participants were provided with a Light Box (SAD3 10000 lux - E.M.S. srl Bologna, Italy) and instructed to expose themselves to light daily for 45 minutes, immediately after getting-up. They were asked to place the Light Box at approximately 60 cm from their head, to one side, and to direct their gaze at the Light Box every 10–15 minutes. If they moved away from the box (for example to go to the toilet or get dressed) they were instructed to make up the lost time at the end of the session. During the entire study period, subjects were asked to maintain regular sleep–wake schedules and avoid significant changes to their habitual consumption of coffee, tea, chocolate and alcoholic beverages. They were also asked to avoid exposure to very bright light and use of mobiles/tablets in the evening and at night. Compliance was checked by phone every third day by one of the researchers.

6-sulfatoxymelatonin (aMT6s) assessment. Urinary samples were kept at −20 °C and aMT6s concentrations measured by radioimmunoassay (Stockgrand Ltd.). Urine samples were analyzed in duplicate and all samples from the same subject were included in the same assay. The inter-assay coefficients of variation (CVs) were 13.3% at 2.4 ng/mL, 8.9% at 10.4 ng/mL, and 15.4% at 17.5 ng/mL (n = 16 at each concentration).

The aMT6s rhythms were evaluated using cosinor analysis, which is based on the least square approximation of the time series using a cosine function with a period of 24 hours. The following parameters were obtained: acrophase time (time of peak aMT6s concentration, or maximum of the fitted cosinor function), mesor (mean aMT6s value for all the samples included in the cosinor analysis) and amplitude (difference between the mesor and the peak aMT6s concentrations). Data were considered acceptable if the cosinor fit, or the likelihood of the aMT6s value for all the samples included in the cosinor analysis) and amplitude (difference between the mesor and the peak aMT6s concentrations). Data were considered acceptable if the cosinor fit, or the likelihood of the aMT6s value for all the samples included in the cosinor analysis) and amplitude (difference between the mesor and the peak time between the pre- and post-light administration was also computed and considered significant when >15 min. All parameters were assessed both pre- and post-light administration and the difference in aMT6s acrophase (peak) time between the pre- and post-light administration was also computed and considered significant when >15 min.

Statistical Analysis. Data are presented as mean ± standard deviation (SD) or 95% Confidence Interval (CI). Clock times are presented as decimal hours (h) within the results section, and as h:mins in Tables and Figures, to facilitate reading, where possible.

Hardy–Weinberg equilibrium was tested by the Pearson χ². Association testing between single polymorphisms and diurnal preference was performed using the Cochran–Armitage test (PLINK open-source whole genome association analysis toolset; http://pngu.mgh.harvard.edu/purcell/plink/). Haplotype testing was conducted using the conditional haplotype-based test module, also on PLINK, which estimates haplotypes to be tested from unphased genotypes. Experiment-wide correction for multiple testing was applied (FDR method, n = 3 tests).

The Student t/Mann–Whitney U test (correction for multiple testing applied where appropriate) and ANOVA/Kruskal-Wallis ANOVA were used to compare sleep–wake variables between two and multiple groups, as appropriate (post-hoc: Tukey/multiple comparisons of mean ranks). Repeated measures ANOVA was utilized to assess the time-course of variables and/or their changes in relation to light administration (post-hoc: Tukey test) (Statistica 13.1, Dell. Round Rock, Texas, US). As hourly KSS/mood data were available for most subjects in the time slot between 9:30 and 21:30 h (at earlier/later times, the numbers decreased significantly), this was the time interval utilized for analysis.

Table 5. Light administration study design. aMT6s: 6-sulphatoxymelatonin. KSS: Karolinska Sleepiness Scale.

| Study Day | 1 Mon | 2 Tue | 3 Wed | 4 Thu | 5 Fri | 6 Sat | 7 Sun | 8 Mon | 9 Tue | 10 Wed | 11 Thu | 12 Fri |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|-------|
| Baseline questionnaires plus provision of Light Box | Hourly KSS | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Morning light administration | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Urine collection for aMT6s | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Sleep diaries | | | | | | | | | | | | |

References
1. Lowrey, P. L. & Takahashi, J. S. Genetics of circadian rhythms in Mammalian model organisms. Adv Genet. 74, 175–230 (2011).
2. Brown, S. A. et al. Molecular insights into human daily behavior. Proc Natl Acad Sci USA 105, 1602–1607 (2008).
3. Yagita, K. et al. Dimerization and nuclear entry of mPER proteins in mammalian cells. Genes Dev. 14, 1353–1363 (2000).
4. Shearman, L. P., Jin, X., Lee, C., Reppert, S. M. & Weaver, D. R. Targeted disruption of the mPer3 gene: subtle effects on circadian clock function. Mol Cell Biol. 20, 6269–6275 (2000).
5. Archer, S. N., Antoñete, U. V., Kyriakopoulou, V., Von Schantz, M. & Dijk, D. J. Inter-individual differences in habitual sleep timing and entrained phase of endogenous circadian rhythms of BMAL1, PER2 and PER3 mRNA in human leukocytes. Sleep. 31, 608–617 (2008).
6. Ebisawa, T. et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep. 2, 342–346 (2001).
7. Archer, S. N. et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 26, 413–415 (2003).
8. Chellappa, S. L. et al. Human melatonin and alerting response to blue-enriched light depend on a polymorphism in the clock gene PER3. J. Clin. Endocrinol. Metab. 97, E433–E437 (2012).
9. Gooley, J. J. Treatment of circadian rhythm sleep disorders with light. Ann. Acad. Med. Singapore. 37, 669–676 (2008).
10. Arendt, J. Managing jet lag: some of the problems and possible new solutions. Sleep Med. Rev. 13, 249–256 (2009).
11. Hida, A. et al. Screening of clock gene polymorphisms demonstrates association of a PER3 polymorphism with morningness-eveningness preference and circadian rhythm sleep disorder. Sci. Rep. 4, 6309, doi:10.1038/srep06309 (2014).
12. Lussier, G. & Larose, L. A casein kinase I activity is constitutively associated with Nck. J. Biol. Chem. 272, 2688–2694 (1997).
13. Pendergast, J. S., Friday, R. C. & Yamazaki, S. Distinct functions of Period2 and Period3 in the mouse circadian system revealed by in vitro analysis. PLoS One. 5, e8552, doi:10.1371/journal.pone.0008552 (2010).
14. Pendergast, J. S., Friday, R. C. & Yamazaki, S. Tissue-specific function of Period3 in circadian rhythmicity. PLoS One. 7, e30254, doi:10.1371/journal.pone.0030254 (2012).
15. Zhang, L. et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. Proc. Natl. Acad. Sci. USA 113, E1536–E1544 (2016).
16. Pereira, D. S. et al. Association of the length polymorphism in the human Per3 gene with the delayed sleep-phase syndrome: do latitude and time of travel have an influence upon it? Sleep. 28, 29–32 (2005).
17. Lázár, A. S. et al. Sleep, diurnal preference, health, and psychological well-being: a prospective single-allele-variation study. Chronobiol. Int. 29, 131–146 (2012).
18. Barclay, N. L. et al. Sleep quality and diurnal preference in a sample of young adults: associations with 5HTTLPR, PER3, and CLOCK 3111. Am. J. Med. Genet. B, Neuropsychiatr. Genet. 156B, 681–690 (2011).
19. Olsand, T. M., Bjorvatn, B. R., Steen, V. M. & Pallesen, S. Association study of a variable-number tandem repeat polymorphism in the clock gene PERIOD3 and chronotype in Norwegian university students. Chronobiol. Int. 28, 764–770 (2011).
20. Perea, C. S. et al. Study of a functional polymorphism in the PER3 gene and diurnal preference in a Colombian sample. Open. Neurol. J. 8, 7–10 (2014).
21. Cachoche, C. et al. High sensitivity of human melatonin, alertness, thermoregulation, and heart rate to short wavelength light. J. Clin. Endocrinol. Metab. 90, 1311–1316 (2005).
22. Lockley, S. W. et al. Short-wavelength sensitivity for the direct effects of light on alertness, vigilance, and the waking electroencephalogram in humans. Sleep. 29, 161–168 (2006).
23. Terman, M. Task force report on light treatment for sleep disorders. J. Biol. Rhythms. 10, 101–176 (1995).
24. Golder, S. A. & Macy, M. W. Diurnal and seasonal mood vary with work, sleep, and daylength across diverse cultures. Science. 333, 1878–1881 (2011).
25. Ferrante, A. et al. Diurnal preference predicts phase differences in expression of human peripheral circadian clock genes. J. Circadian Rhythms. 5, 13–14 (2015).
26. Johansson, C. et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology. 28, 734–9 (2003).
27. Ojeda, D. A. et al. A novel association of two non-synonymous polymorphisms in PER2 and PER3 genes with specific diurnal preference subscales. Neurosci. Lett. 553, 52–6 (2013).
28. Horne, J. A. & Ousberg, O. A. Self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int. J. Chronobiol. 4, 97–110 (1976).
29. Buysee, D. J., Reynolds, C. E., Monk, T. H., Berman, S. R. & Kupfer, D. J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213 (1989).
30. Åkerstedt, T. & Gillberg, M. Subjective and objective sleepiness in the active individual. Int. J. Neurosci. 18, 214–221 (1981).
31. Manfredini, D. S. & Waterhouse, J. M. Mathematical and statistical analysis of circadian rhythms. Psychoneuroendocrinology. 13, 443–464 (1988).
32. Arendt, J., Middleton, B., Williams, P., Francis, G. & Luke, C. Sleep and circadian phase in a ship’s crew. J. Biol. Rhythms. 21, 214–221 (2006).
33. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).

Acknowledgements
We are most grateful to all the volunteers who took part in the study for their time and their enthusiasm. We also wish to thank Giovanni Vazza (Department of Biology, University of Padova) for statistical advice and support. The work was part-funded by a grant from the Italian Ministry of Health to Sara Montagnese (GR-2009-1604309) and by a National Research Council of Italy grant (EPIGEN Progetto Bandiera Epigenomica – subproject 4) to Rodolfo Costa.

Author Contributions
M.T., C.D.P., D.J.S., S.M., R.C.: designed the study. M.T., M.C., M.B., F.C., M.S., D.M., S.M.: performed the phenotypic research. A.B., L.C., G.M., C.D.P.: performed the molecular genetics research. M.T., A.B., M.C., L.C., M.B., F.C., M.S., C.S., G.M., C.D.P., B.M., Š.M., R.C.: analyzed the data. M.T., D.J.S., S.M., R.C.: wrote the manuscript. A.B., G.M., C.D.P.: reviewed the manuscript. S.M., R.C.: acquired the funding.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-06769-w

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
